Generic placeholder image

Endocrine, Metabolic & Immune Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5303
ISSN (Online): 2212-3873

Stearoyl-CoA Desaturase: A Vital Checkpoint in the Development and Progression of Obesity

Author(s): Hemant Poudyal and Lindsay Brown

Volume 11, Issue 3, 2011

Page: [217 - 231] Pages: 15

DOI: 10.2174/187153011796429826

Price: $65

Abstract

Stearoyl-CoA desaturase 1 (SCD-1) is the rate-limiting enzyme that catalyses the conversion of saturated to monounsaturated fatty acids. Increased SCD-1 expression and activity have been implicated in cancer, cardiovascular diseases, insulin resistance and obesity. Studies with humans, wild-type rodents, knock-out mice and cells in culture show that SCD-1 inhibition decreases lipogenesis and increases GLUT4-mediated glucose uptake in skeletal muscle. In this review, we will evaluate the role of SCD-1 as a homeostatic check-point between glucose and fatty acid metabolism in the development and progression of obesity. In addition to the role of SCD-1 in glucose and fatty acid metabolism, we will also discuss the expression and regulation of SCD-1, its specific interactions with inflammatory responses and PPARs, the role of SCD-1 derived MUFAs in obesity and the relevance of SCD desaturation index as a predictor of obesity and metabolic syndrome. Additionally, we will explore the prospects of SCD-1 as a potential drug target for the management of obesity and related disorders.

Keywords: Stearoyl-CoA desaturase, SCD-1, metabolic syndrome, PPAR, desaturation index, MUFA, obesity, catalyses, fatty acids, insulin resistance, lipogenesis, skeletal muscle, glucose


Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy